{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:52:41Z","timestamp":1781650361259,"version":"3.54.5"},"reference-count":17,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Talquetamab is a G protein\u2013coupled receptor class C group 5 member D T-cell\u2013engaging antibody, approved for relapsed\/refractory multiple myeloma (RRMM). In the MonumenTAL-1 clinical trial, cytokine release syndrome (CRS) occurred at a frequency of 77%; however, there was no assessment of CRS rates by step-up dose. The primary objective of this study was to characterize CRS rates after each talquetamab step-up dose in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Patients with RRMM who completed the talquetamab once a week or once every 2 weeks step-up dosing schedule between September 2023 and November 2024 were identified via the institutional database. CRS rate after each talquetamab step-up dose was compared using the chi-square\/Fisher\u2019s exact test. The Kruskal-Wallis test was used to compare difference in median time to the CRS onset. Multivariate logistic regression analysis was performed to identify predictors of CRS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Fifty patients completed the talquetamab step-up dosing phase during the study period; CRS occurred at a rate of 80%. Pairwise comparisons revealed significant differences in CRS rates between the fourth dose (4%) and each of step-up dose 1 (28%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .014) and 2 (34%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .003). The only CRS event with fourth dose was grade 1. The median time to onset of first CRS did not differ significantly between step-up doses (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .441). Previous exposure to T-cell\u2013redirecting therapy had no impact on CRS incidence (odds ratio: 0.20 [95% CI, 0.03 to 1.10]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Our findings suggested that the fourth talquetamab dose could be administered in outpatient settings given its high tolerability. The reduced hospitalization period for talquetamab step-up dosing could reduce health care expenses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-25-00224","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:59:27Z","timestamp":1758052767000},"page":"1105-1111","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses"],"prefix":"10.1200","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6628-0795","authenticated-orcid":true,"given":"Issam S.","family":"Hamadeh","sequence":"first","affiliation":[{"name":"Clinical Pharmacy Services, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Modelevsky","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Services, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0252-8883","authenticated-orcid":true,"given":"Amelia","family":"Chan","sequence":"additional","affiliation":[{"name":"Drug Policy and Quality &amp; Safety, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3639-3515","authenticated-orcid":true,"given":"Aaron","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross S.","family":"Firestone","sequence":"additional","affiliation":[{"name":"Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice X.","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Services, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tala","family":"Shekarkhand","sequence":"additional","affiliation":[{"name":"Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-4318","authenticated-orcid":true,"given":"Neha","family":"Korde","sequence":"additional","affiliation":[{"name":"Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-6495","authenticated-orcid":true,"given":"Malin L.","family":"Hultcrantz","sequence":"additional","affiliation":[{"name":"Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[{"name":"Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-9561","authenticated-orcid":true,"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[{"name":"Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2036-1749","authenticated-orcid":true,"given":"Hani","family":"Hassoun","sequence":"additional","affiliation":[{"name":"Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-1091","authenticated-orcid":true,"given":"Urvi A.","family":"Shah","sequence":"additional","affiliation":[{"name":"Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-4854","authenticated-orcid":true,"given":"Kylee","family":"Maclachlan","sequence":"additional","affiliation":[{"name":"Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3458-824X","authenticated-orcid":true,"given":"Sridevi","family":"Rajeeve","sequence":"additional","affiliation":[{"name":"Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[{"name":"Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhwani","family":"Patel","sequence":"additional","affiliation":[{"name":"Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":true,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[{"name":"Transplant and Cellular Therapy Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9484-0240","authenticated-orcid":true,"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[{"name":"Transplant and Cellular Therapy Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":true,"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[{"name":"Transplant and Cellular Therapy Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":true,"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[{"name":"Transplant and Cellular Therapy Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":true,"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-2594","authenticated-orcid":true,"given":"Carlyn R.","family":"Tan","sequence":"additional","affiliation":[{"name":"Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","first-page":"1","article-title":"Moving toward a cure for myeloma","volume":"42","author":"Mateos MV","year":"2022","unstructured":"Mateos MV, Nooka AK, Larson SM: Moving toward a cure for myeloma. Am Soc Clin Oncol Educ Book 42:1-12, 2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012854"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020217"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.07.028"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012354"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_6_10_2","volume-title":"Talvey [package Insert]","year":"2023","unstructured":"Talvey [package Insert]. Horsham, PA. Janssen Biotech; 2023"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011225"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012724"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181936"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e13626"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00963-y"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.132"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203426"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-00224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:01:15Z","timestamp":1781647275000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-00224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/OP-25-00224"],"URL":"https:\/\/doi.org\/10.1200\/op-25-00224","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-03-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}